Tularemia (Oculoglandular)

Oculoglandular Tularemia

Oculoglandular tularemia is a rare clinical form of tularemia caused by Francisella tularensis, presenting as unilateral granulomatous conjunctivitis with regional lymphadenopathy (Parinaud's oculoglandular syndrome) following direct conjunctival inoculation.[1-2] It accounts for approximately 3% of tularemia cases and carries a[3] complication rate of ~31.5%, largely driven by delayed diagnosis (mean time to diagnosis ~41 days).[4]

1. History

• Mechanism of conjunctival inoculation: touching eyes after handling infected animals (rabbits, hares, rodents), splash of contaminated water, self-inoculation from tick/fly bite site, or aerosol exposure[1][5]
• Onset and timing: incubation period 3–5 days (range 1–21 days); sudden onset of eye pain, redness, tearing, and fever[1][6]
• Symptom characterization: unilateral eye burning/pain, photophobia, excessive lacrimation, blurred vision, periorbital swelling[6-7]
• Associated symptoms: fever, chills, headache, malaise, fatigue, myalgia, anorexia[1][7]
• Progression: painful preauricular or submandibular swelling developing days after ocular symptoms[4]
• Important negatives: no bilateral involvement (typically unilateral), no purulent discharge initially (granulomatous, not bacterial conjunctivitis pattern), no cough/dyspnea (rules out pneumonic form)

2. Alarm Features

• Vision impairment or loss — suggests corneal involvement or severe orbital inflammation[7]
• Rapidly enlarging, fluctuant lymph nodes — indicates suppuration (occurs in ~30% of lymphadenopathy cases)[1][4]
• High fever (>39°C) with confusion, stupor, or hemodynamic instability — suggests progression to typhoidal/septic form[1-2]
• Cough, dyspnea, or pleuritic chest pain — hematogenous spread to lungs (secondary pneumonic tularemia)[2]
• Meningeal signs — rare but reported complication (meningitis, brain abscess)[1]
• Immunocompromised host — associated with unusual, severe, and atypical presentations[7-8]
• Delayed diagnosis >2–3 weeks — significantly increases complication rate and treatment failure[4][9]

3. Medications

First-line treatment (mild-moderate oculoglandular form)

• Ciprofloxacin 500 mg PO BID × 10–14 days, or doxycycline 100 mg PO BID × 14–21 days[5-6][10]
• The 2025 CDC guidelines designate fluoroquinolones and doxycycline as first-line for outbreaks of any size[10]
• Fluoroquinolones have lower relapse rates (~5–10%) compared to doxycycline (~10–15%)[1]

Severe or systemic disease

• Gentamicin 5 mg/kg/day IV daily (or divided q8h) × minimum 10 days[5-6]
• Streptomycin 1 g IM BID × minimum 10 days (if available)[5]

Contraindicated/ineffective

• Beta-lactams — F. tularensis is intrinsically resistant[5][9]
• Most macrolides — generally ineffective (azithromycin may have limited role in type B strains)[1][9]
• Anti-tuberculosis agents — ineffective[9]

Cautions

• Fluoroquinolones: use with caution in pregnancy and young children (musculoskeletal concerns), though ciprofloxacin has been used safely in children aged 1–10[1]
• Doxycycline: avoid in children <8 years for prolonged courses; adjust aminoglycosides for renal function[5]
• Pregnant women with severe disease: gentamicin preferred[1]

4. Diet

• No specific dietary triggers or restrictions
• Ensure adequate hydration, especially with fever and systemic illness
• Avoid consumption of undercooked wild game (rabbits, hares) and untreated water from endemic areas as a preventive measure[1][8]

5. Review of Systems

• Eyes: pain, redness, photophobia, tearing, vision changes (unilateral)
• HEENT: preauricular/submandibular/cervical swelling or tenderness, sore throat (rule out oropharyngeal form)
• Constitutional: fever, chills, night sweats, weight loss, fatigue
• Respiratory: cough, dyspnea, chest pain (screen for pneumonic involvement)
• GI: nausea, vomiting, diarrhea, abdominal pain (typhoidal features)
• Neurologic: headache, confusion, neck stiffness (meningitis screening)
• Skin: rashes (erythema nodosum), ulcers elsewhere (concurrent ulceroglandular form)
• MSK: myalgia, arthralgia

6. Collateral History and Family History

• Critical exposure history: contact with wild rabbits, hares, rodents, or their carcasses; tick or deerfly bites; exposure to contaminated water; outdoor occupational or recreational activities (hunting, farming, landscaping)[3][5][8]
• Geographic context: endemic areas in the Northern Hemisphere — south-central US (Arkansas, Missouri, Oklahoma), Scandinavia, Turkey, Central Europe[3][8]
• Seasonal pattern: peak incidence in summer months (tick/arthropod season)[3]
• Cat exposure: cats can transmit F. tularensis through bites or scratches[5][11]
• Laboratory workers: occupational risk from handling specimens[5]
• Family history is generally not relevant (not a hereditary condition)

7. Risk Factors

• Handling infected animals (especially rabbits, hares) — key risk factor for oculoglandular form specifically[1]
• Tick bites (Dermacentor, Amblyomma species) — most common transmission route overall (69% of US cases)[3]
• Deerfly bites[5]
• Contaminated water exposure — splashing face/eyes[4]
• Outdoor occupations: hunters, trappers, farmers, veterinarians, landscapers[8]
• Male sex (65% of cases)[3]
• Immunocompromised status — worse prognosis and atypical presentations[1][7]
• Older age — systemic disease more common[3]
• Laboratory exposure without proper biosafety precautions[5]

8. Differential Diagnosis

• The oculoglandular presentation falls under Parinaud's oculoglandular syndrome (unilateral granulomatous conjunctivitis + regional lymphadenopathy). Key differentials:[12-15]
• Cat scratch disease (Bartonella henselae) — most common cause of Parinaud's oculoglandular syndrome; history of cat scratch/bite near eye; positive Bartonella serology[14][16]
• Adenoviral conjunctivitis — typically bilateral, follicular, no suppurative lymphadenopathy
• Sporotrichosis (Sporothrix spp.) — ocular inoculation from contaminated plant material or cat scratch; culture-confirmed[13]
• Tuberculosis — chronic granulomatous conjunctivitis; PPD/IGRA positive
• Chlamydial inclusion conjunctivitis — mucopurulent, bilateral, sexually active young adults
• Yersinia enterocolitica/pseudotuberculosis — rare cause of Parinaud's syndrome[15]
• Lymphoma/sarcoidosis — chronic conjunctival lesion with lymphadenopathy; biopsy needed
• Herpes simplex keratoconjunctivitis — dendritic ulcer on fluorescein, vesicular lid lesions
• Distinguishing features for tularemia: exposure to wild animals/ticks, endemic area, severe systemic toxicity disproportionate to eye findings, conjunctival ulceration with chemosis and vasculitis[2]

9. Past Medical History

• Immunocompromising conditions (HIV, transplant, chemotherapy, chronic steroids) — associated with severe and atypical manifestations[1][7]
• Previous tularemia — prior infection may confer partial immunity
• Chronic eye conditions — may confound or delay diagnosis
• Renal impairment — affects aminoglycoside dosing[5]
• Diabetes — may predispose to more severe infection[15]

10. Physical Exam

Vital signs

• Fever (often high, >38.5°C), tachycardia

Eye exam

• Unilateral conjunctival injection with chemosis[2]
• Conjunctival ulceration or granulomatous nodules — hallmark finding[1-2]
• Pronounced periorbital edema
• Excessive tearing (epiphora)[6]
• Assess visual acuity — may be impaired[7]
• Slit-lamp exam: look for corneal involvement, anterior chamber reaction

Lymph node exam

• Preauricular lymphadenopathy — most characteristic[4][12]
• Submandibular lymphadenopathy[4]
• Cervical lymphadenopathy[1]
• Assess for fluctuance (suppuration) or fistulization[1]

General

• Assess for hepatosplenomegaly (systemic spread)
• Skin survey for concurrent ulcers, erythema nodosum, or tick bite sites[1]
• Lung auscultation for crackles (secondary pneumonia)

11. Lab Studies

Diagnostic

• Serology (microagglutination test, MAT): preferred diagnostic method; titer ≥1:160 or 4-fold rise between acute and convalescent specimens (2 weeks apart)[4-5]
• PCR of conjunctival swab or lymph node aspirate — rapid, specific[5]
• Culture: requires cysteine-supplemented media (e.g., chocolate agar with IsoVitaleX); routine cultures often negative; must notify lab due to biosafety risk (BSL-3 pathogen)[5]
• Direct fluorescent antibody (DFA) on clinical specimens[6]

Supportive labs (expected abnormalities)

• Leukocytosis[6]
• Elevated ESR[6]
• Thrombocytopenia[6]
• Hyponatremia[6]
• Elevated hepatic transaminases[6]
• Elevated CPK, myoglobinuria[6]
• Sterile pyuria[6]

Monitoring

• Renal function (BUN/Cr) if using aminoglycosides
• CBC, LFTs for treatment monitoring

12. Imaging

• Imaging is generally unnecessary for uncomplicated oculoglandular tularemia
• CT of the neck/face: consider if lymph node suppuration suspected — evaluate for abscess formation requiring drainage[1][9]
• Orbital CT/MRI: if concern for orbital extension or preseptal/orbital cellulitis[16]
• Chest X-ray or CT: obtain if respiratory symptoms develop — look for hilar adenopathy, infiltrates, pleural effusion (secondary pneumonic spread)[2][6]

13. Special Tests

• Slit-lamp examination: essential to characterize conjunctival granulomas, ulceration, and rule out corneal involvement
• Conjunctival biopsy: may show necrotizing granulomatous inflammation; can be sent for PCR and culture[12][16]
• Lymph node FNA or biopsy: if suppuration present; send for culture (with lab notification), PCR, and histopathology[9]
• Fluorescein staining: rule out corneal ulceration

14. ECG

• Not routinely indicated
• Consider if systemic toxicity or sepsis is present
• Myocarditis is a very rare but reported complication of tularemia — obtain ECG and troponin if chest pain, arrhythmia, or heart failure symptoms develop[11]

15. Assessment

• Clinical summary: Oculoglandular tularemia presents as a unilateral painful granulomatous conjunctivitis with conjunctival ulceration, chemosis, and ipsilateral preauricular/submandibular lymphadenopathy, accompanied by systemic symptoms (fever, malaise, myalgia). It results from direct conjunctival inoculation with F. tularensis.[1-2]

Severity stratification

• Mild-moderate: localized conjunctivitis + lymphadenopathy, low-grade fever, hemodynamically stable → outpatient oral antibiotics
• Severe: high fever, lymph node suppuration, vision threat, systemic toxicity, immunocompromised host → IV aminoglycosides, inpatient management

Typical vs. atypical

• Typical: unilateral red eye + preauricular node + fever + animal/tick exposure
• Atypical: bilateral involvement, absence of lymphadenopathy, orbital mass, or concurrent skin ulcers

Complications

• Lymph node suppuration (~30%)[1]
• Corneal ulceration/perforation
• Vision loss[7]
• Hematogenous spread → pneumonia, sepsis, meningitis[2]
• Chronic/relapsing course if treatment delayed[9]

16. Treatment Plan

Initial stabilization

• Assess hemodynamic stability; IV fluids and antipyretics as needed

Mild-moderate (outpatient)

• Ciprofloxacin 500 mg PO BID × 10–14 days (preferred for lower relapse rate)[1][5][10]
• OR Doxycycline 100 mg PO BID × 14–21 days[5][10]

Severe (inpatient)

• Gentamicin 5 mg/kg/day IV (once daily or divided q8h) × minimum 10–14 days[5-6]
• OR Streptomycin 1 g IM BID × minimum 10 days[5]
• Step-down to oral fluoroquinolone or doxycycline once clinically improved[5]

Adjunctive

• Warm compresses to the eye
• Topical ophthalmic antibiotics (e.g., fluoroquinolone drops) for local comfort, though systemic therapy is the mainstay
• Surgical drainage of suppurative lymph nodes if they fail to resolve with antibiotics[1][9]

Children

• Gentamicin 2.5 mg/kg IV q8h (or 6 mg/kg/day divided q8h) × minimum 10 days[5-6]
• Ciprofloxacin 15 mg/kg PO/IV BID × minimum 10 days[6]

Pregnancy

• Gentamicin for severe disease; azithromycin may be considered for mild type B infections in select settings[1]

17. Disposition

Admission criteria

• Systemic toxicity, high fever, hemodynamic instability
• Suspected or confirmed lymph node suppuration requiring drainage
• Vision-threatening complications
• Immunocompromised patients
• Need for IV aminoglycoside therapy
• Inability to tolerate oral medications

Discharge criteria

• Hemodynamically stable, afebrile or defervescing
• Tolerating oral antibiotics
• No vision-threatening findings
• Reliable follow-up arranged

Observation indications

• Diagnostic uncertainty with pending serology
• Borderline systemic symptoms

Specialist consultation triggers

• Ophthalmology: all cases — for slit-lamp exam, corneal assessment, and monitoring
• Infectious disease: severe or complicated cases, immunocompromised hosts, treatment failure/relapse
• Surgery: suppurative lymph nodes requiring incision and drainage[9]
• Public health notification: tularemia is a nationally notifiable disease — report to local/state health department[8]

18. Follow Up / Return Precautions

Follow-up timing

• Ophthalmology follow-up within 48–72 hours of initiating treatment
• Repeat clinical assessment at 1–2 weeks to evaluate treatment response
• Convalescent serology at 2–4 weeks to confirm diagnosis (4-fold titer rise)[4]
• Monitor lymph nodes for suppuration for several weeks to months (can occur up to 22–24 months post-infection)[17]
• Return precautions — instruct patient to return immediately for:
• Worsening eye pain, vision changes, or new eye symptoms
• Increasing lymph node size, redness, or drainage
• Persistent or recurrent fever after 48–72 hours of appropriate antibiotics
• New cough, chest pain, or shortness of breath
• Confusion, severe headache, or neck stiffness

Patient counseling

• Tularemia is not transmitted person-to-person; standard precautions are adequate[18]
• Full antibiotic course is essential — relapse rates are high with incomplete treatment or delayed initiation[9]
• Recovery may take weeks to months; progressive debility is common even with treatment[2]
• Prevention: use gloves when handling wild animals, use insect repellent (DEET), perform tick checks, avoid untreated water in endemic areas[7-8]

References

1. Tularaemia: Clinical Aspects in Europe. — Maurin M, Gyuranecz M. The Lancet. Infectious Diseases. 2016.

2. Tularemia as a Biological Weapon: Medical and Public Health Management. — Dennis DT, Inglesby TV, Henderson DA, et al. The Journal of the American Medical Association. 2001.

3. Clinical Recognition and Management of Tularemia in Missouri: A Retrospective Records Review of 121 Cases. — Weber IB, Turabelidze G, Patrick S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2012.

4. Water-Borne Oculoglandular Tularemia: Two Complicated Cases and a Review of the Literature. — Copur B, Surme S. Travel Medicine and Infectious Disease. 2022.

5. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America. — Stevens DL, Bisno AL, Chambers HF, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2014.

6. Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Management of Tick-Borne Illness in the United States. — Ho BM, Davis HE, Forrester JD, et al. Wilderness & Environmental Medicine. 2021.

7. Tickborne Diseases of the United States: A Reference Manual for Healthcare Providers Sixth Edition. — Nancy Shadick MD MPH, Nancy Maher MPH, Dennis Hoak MD United States Centers for Disease Control and Prevention (2022). 2022.

8. Tularemia for Clinicians: An Up-to-Date Review on Epidemiology, Diagnosis, Prevention and Treatment. — Antonello RM, Giacomelli A, Riccardi N. European Journal of Internal Medicine. 2025.

9. Tularemia Treatment: Experimental and Clinical Data. — Maurin M, Pondérand L, Hennebique A, et al. Frontiers in Microbiology. 2023.

10. Tularemia Antimicrobial Treatment and Prophylaxis: CDC Recommendations for Naturally Acquired Infections and Bioterrorism Response - United States, 2025. — Nelson CA, Meaney-Delman D, Fleck-Derderian S, Winberg J, Mead PS. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 2025.

11. Tularemia: An Experience of 13 Cases Including a Rare Myocarditis in a Referral Center in Eastern Switzerland (Central Europe) and a Review of the Literature. — Frischknecht M, Meier A, Mani B, et al. Infection. 2019.

12. Parinaud's Oculoglandular Syndrome Attributable to an Encounter With a Wild Rabbit. — Thompson S, Omphroy L, Oetting T. American Journal of Ophthalmology. 2001.

13. Parinaud's Oculoglandular Syndrome: Coinfection by Bartonella Henselae and Sporothrix Brasiliensis. — Suzuki NN, Mitsuushi GN, Dos Santos LS, et al. Acta Tropica. 2024.

14. Cat Scratch Disease Bacilli in the Conjunctiva of Patients With Parinaud's Oculoglandular Syndrome. — Wear DJ, Malaty RH, Zimmerman LE, Hadfield TL, Margileth AM. Ophthalmology. 1985.

15. Ocular Involvement in Yersinia Enterocolitica Infection Presenting as Parinaud's Oculoglandular Syndrome. — Chin GN, Noble RC. American Journal of Ophthalmology. 1977.

16. Application of Polymerase Chain Reaction Assay in the Diagnosis of Orbital Granuloma Complicating Atypical Oculoglandular Cat Scratch Disease. — Dondey JC, Sullivan TJ, Robson JM, Gatto J. Ophthalmology. 1997.

17. Multifaceted effects of F rancisella tularensis on human neutrophil function and lifespan. — Kinkead LC, Allen LA. Immunological Reviews. 2016.

18. Clinical Management of Potential Bioterrorism-Related Conditions. — Adalja AA, Toner E, Inglesby TV. The New England Journal of Medicine. 2015.